<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756650</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885NTR01</org_study_id>
    <nct_id>NCT02756650</nct_id>
  </id_info>
  <brief_title>1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement</brief_title>
  <acronym>Behcet</acronym>
  <official_title>An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the
      clinical and inflammatory findings of Behced Disease patients with neurologic and vascular
      involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Resolution of acute exacerbation findings related to Behçet's Disease (BD)
      based on achievements in any of the following items without deterioration on day 30:

      For patients with parenchymal neurologic disease: Resolution of acute exacerbation of
      parenchymal neurologic findings based on improvements in any of the following items without
      deterioration on Day 30:

        -  Improvement of muscle strength, ataxia, or other relevant neurologic findings depending
           on the involved region on neurological examination (by Neuro-Behçet's Disease Score,
           Modified Expanded Disability Status Scale, and Modified Rankin Scores) cerebrospinal
           fluid

        -  Improvement in systemic inflammatory findings (CRP, Erythrocyte Sedimentation Rate ,
           SAA)

        -  Any decrease in the size of the MRI lesion, or disappearance of contrast enhancement

        -  Improvement in patients' and physicians global assessment using a 10-cm visual analogue
           scale (VAS)

      Complete response was defined as full clinical recovery to the pre-attack state,
      disappearance of MRI lesion(s), and normalisation of Cerebrospinal Fluid findings.

      Partial response was defined as partial improvement in clinical findings, but with findings
      still worse than the pre-attack state, and MRI lesions, which become smaller with no or less
      enhancement, and a decrease in cerebrospinal fluid cell count.

      Non-response was defined as no improvement in clinical findings, no change on MRI, no change
      in cerebrospinal fluid parameters, or worsening in those findings.

      For patients with large vessel vascular disease: Resolution of acute vascular exacerbation
      findings related to Behçet's Disease based on achievements in any of the following items
      without deterioration at 1 month:

        -  Improvement in relevant symptoms (localised pain, abdominal pain, calf thickness,
           haemoptysis) by using physician and patient's global assessment with VAS

        -  Improvement in systemic inflammatory findings (CRP, ESR, SAA)

        -  Any improvement in radiological findings depending on the involved vessels (MR, CT or
           Doppler findings)

        -  Improvement in patients' and physicians global assessment using a 10-cm visual analogue
           scale (VAS)

      Complete response was defined as clinical and laboratory improvement based on ≥50%
      improvements in patient's and physician's global assessments by using VAS, and ≥50% reduction
      in CRP values; along with stable or ≥20% reduced aneurysm size in patients with arterial
      involvement, and stable or ≥20% reduced calf swelling in patients with lower extremity venous
      thrombosis.

      Partial response was defined as clinical and laboratory improvement based on observations of
      an improvement between 20-49% according to patient's and physician's global assessments by
      using VAS, 20-49% reduction in CRP values; along with stable or less than 20% reduced
      aneurysm size in patients with arterial involvement, and stable or less than 20% reduced calf
      swelling in patients with lower extremity thrombosis.

      Non-response will be defined as observing no or less than 20% clinical improvement by
      patient's and physician's global VAS or worsening of clinical findings, no change or increase
      in acute phase response, increase in aneurysm size for patients with arterial involvement or
      progression of venous thrombosis in patients with venous involvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Attacks</measure>
    <time_frame>30 days</time_frame>
    <description>Resolution of acute exacerbation findings related to Behçet's Disease (BD). The attacks were assessed by pyhsician global assesment.
For patients with parenchymal neurologic disease: Resolution of acute exacerbation of parenchymal neurologic findings based on improvements in any of the following items without deterioration on Day 30
This was an exploratory trial that was not powered for a statistical analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>30 days</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. Scale range is between 0-10 with 10 being most disability. Mean score of 3 participants who were evaluated in Neurology clinic. Other 5 participants were not evaluated for EDSS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuro-Behçet's Disability Score (NBDS)</measure>
    <time_frame>30 days</time_frame>
    <description>Neuro-Behçet's disability score (NBDS) has been proposed for parenchymal-NBD patients to quantify disabilities. This comprises scores for motor and cognitive status. NBDS is the arithmetic sum of both scores and ranges from 0 to 8, with 8 being death due to NBD. 3 neurologic participants were evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Ranking Score (mRS)</measure>
    <time_frame>30 days</time_frame>
    <description>Mean Modified Rankin Scale (mRS): mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scores range from 0-5 with 5 being the worst outcome. Only 3 participants from neurology clinic were evaluated with this scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ataxia</measure>
    <time_frame>30 days</time_frame>
    <description>Number of the partcipants with ataxia. 3 participants from neurology clinic were evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination Scores Indicating Change in Muscle Strength</measure>
    <time_frame>30 days</time_frame>
    <description>All 4 extremties were evaluated for muscle strength (upper right, upper left, lower right and lower left) fro each patient. Score 0 is the worst outcome whereas 5 is the best outcome for muscle strength. 3 participants from neurology clinic were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein (CRP) Values</measure>
    <time_frame>30 days</time_frame>
    <description>Mean CRP (C-reactive protein) value (8 participants)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>30 days</time_frame>
    <description>Mean erythrocyte sedimentation rate (ESR) value (8 participants)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAA (Serum Amyloid A)</measure>
    <time_frame>30 days</time_frame>
    <description>Mean Serum Amyloid A value (8 participants)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoptysis</measure>
    <time_frame>30 days</time_frame>
    <description>The number of the participants with hemoptysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scores (VAS) for Headache</measure>
    <time_frame>30 days</time_frame>
    <description>Headache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. Physician and participant determined the VAS score separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scores (VAS) for Stomachache</measure>
    <time_frame>30 days</time_frame>
    <description>Stomacheache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. VAS is determined separately by physician and the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scores (VAS) for Extremity Assessments</measure>
    <time_frame>30 days</time_frame>
    <description>Extremity assessments were measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst possible pain''. The physicians and participants evaluated VAS separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scores (VAS) for Patients' General Assessments</measure>
    <time_frame>30 days</time_frame>
    <description>Participants assessed their own well-being with VAS (visual analogue scale). Score 0 means the best outcome, score 10 is the worst outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>30 days</time_frame>
    <description>Physician's General Assessments is VAS scale, ranging between 0-5, showing the disease status of participants. Score 0 is the worst outcome; 5 is the best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steroid Dose Regimen</measure>
    <time_frame>30 days</time_frame>
    <description>Mean steroid treatment dose (8 participants)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BDCAF (Behçet's Disease Current Activity Form)</measure>
    <time_frame>30 days</time_frame>
    <description>BDCAF is an assessment that is made by physician for evaluating the disease activity in last four weeks. Score range is 0 to 12, 0 is the best outcome, 12 is the worst outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extremity (Localized) Pain Assessment (VAS)</measure>
    <time_frame>30 days</time_frame>
    <description>Localized pain in the extremities were assessed by visual analogue scale scores ranging between Scale; 0 is the best outcome; 10 is worst.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Behcet Disease</condition>
  <arm_group>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab was administered monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)</description>
    <arm_group_label>Canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged over 18-60 Behced Disease fulfilling the International Study Group (ISG)
        criteria, who have a recent exacerbation of large-vessel vascular disease and/or
        parenchymal neurologic disease For Neurologic Involvement

          -  Patients experiencing an acute exacerbation of parenchymal neurologic disease
             involving brainstem and/or diencephalic region.

          -  Exacerbation is defined based on the presence of both of the following:

          -  An acute/subacute neurological syndrome including any of hemiparesis, ataxia,
             dysarthria,headache within the first month of onset of neurologic manifestations
             (without any prior high dose steroid treatment)

          -  Compatible cranial MRI lesion involving brainstem and/or diencephalic region

        For Vascular Disease :

        Patients experiencing an acute exacerbation of vascular disease within the last month,
        involving

          -  Large arteries (abdominal aorta, pulmonary arteries, extremity arteries)

          -  Large veins (deep vein thrombosis of extremities, caval vein thrombosis, dural sinus
             thrombosis)

          -  Compatible radiological findings (spiral CT, MR, or Doppler ultrasonography)

        Exclusion Criteria:

        For Neurologic Involvement :

          -  Presence of severe neurological sequelae from any previous attacks rendering the
             patient dependent on others physically or mentally

          -  Any other neurological cause underlying the picture including ischemic central nervous
             system lesion on MRI

          -  Any previous treatment with biological agents other than interferon-alpha or any
             previous treatment with cyclophosphamide

          -  No interferon in the last 6 months, no Intra Venous Metilprednizolon in the past month

        For Vascular disease and general :

          -  Presence of severe vascular sequelae from any previous attacks rendering the patient
             dependent on others

          -  Any other vascular disease complication the evaluation of exacerbation

          -  Any previous treatment with biological agents other than interferon alpha, or any
             previous treatment with cyclophosphamide

          -  No interferon alpha in the last 6 months, no IVMP in the past month

          -  History of Squamo Cell Carcinoma OR Basal Cell Carcinoma in previous 5 years. General

          -  Presence or history of any other inflammatory rheumatic disease

          -  Positive Purified Protein Derivative test (according to local guidance) where an
             active Tuberculosis infection cannot be excluded via Quantiferon (T-Spot or
             radiographic imaging if needed) Pregnancy or lactation

          -  Presence of any active or chronic infection or any major episode of infection
             requiring hospitalization or treatment with i.v. antibiotics within 30 days or oral
             antibiotics within 14 days prior to screening

          -  History or a malignancy within the last 5 years, except for successfully excised
             squamous or basal cell carcinoma of the skin

          -  Women of childbearing potential not using the contraception method(s) specified in
             this study, as well as women who are breastfeeding

          -  With known sensitivity to canakinumab

          -  Use of any other investigational agent in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmet Gül, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>IU Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murat Kurtuncu, Ass.Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>IU Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gulsen Akman Demir, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bilim University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Behcet Disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Immune system</keyword>
  <keyword>Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The publication has been planned for Q4 2020.</ipd_time_frame>
    <ipd_access_criteria>Access from peer reviewed journal</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02756650/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>8 subjects enrolled 5 subjects were evaluated in Rheumatology clinic. 3 subjects were evaluated in Neurology clinic.</recruitment_details>
      <pre_assignment_details>Ten patients were planned to be enrolled. Nine patients were screened. Eight patients were enrolled. Six patients completed the study. One patient was dropped out in the 7th visit because of an unknown drug abuse. One patient was dropped out in the 11th visit because of adverse event, worsening in pulmonary artery aneurysm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACZ885N</title>
          <description>Canakinumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set</population>
      <group_list>
        <group group_id="B1">
          <title>ACZ885N</title>
          <description>Canakinumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.25" spread="2.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Attacks</title>
        <description>Resolution of acute exacerbation findings related to Behçet's Disease (BD). The attacks were assessed by pyhsician global assesment.
For patients with parenchymal neurologic disease: Resolution of acute exacerbation of parenchymal neurologic findings based on improvements in any of the following items without deterioration on Day 30
This was an exploratory trial that was not powered for a statistical analysis.</description>
        <time_frame>30 days</time_frame>
        <population>Intent-to-Treat (ITT) population: all 8 subjects who took at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Attacks</title>
          <description>Resolution of acute exacerbation findings related to Behçet's Disease (BD). The attacks were assessed by pyhsician global assesment.
For patients with parenchymal neurologic disease: Resolution of acute exacerbation of parenchymal neurologic findings based on improvements in any of the following items without deterioration on Day 30
This was an exploratory trial that was not powered for a statistical analysis.</description>
          <population>Intent-to-Treat (ITT) population: all 8 subjects who took at least one dose of study medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Modified Expanded Disability Status Scale (EDSS)</title>
        <description>The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. Scale range is between 0-10 with 10 being most disability. Mean score of 3 participants who were evaluated in Neurology clinic. Other 5 participants were not evaluated for EDSS.</description>
        <time_frame>30 days</time_frame>
        <population>Behçet’s Disease set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Expanded Disability Status Scale (EDSS)</title>
          <description>The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. Scale range is between 0-10 with 10 being most disability. Mean score of 3 participants who were evaluated in Neurology clinic. Other 5 participants were not evaluated for EDSS.</description>
          <population>Behçet’s Disease set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neuro-Behçet's Disability Score (NBDS)</title>
        <description>Neuro-Behçet's disability score (NBDS) has been proposed for parenchymal-NBD patients to quantify disabilities. This comprises scores for motor and cognitive status. NBDS is the arithmetic sum of both scores and ranges from 0 to 8, with 8 being death due to NBD. 3 neurologic participants were evaluated.</description>
        <time_frame>30 days</time_frame>
        <population>Behçet’s disease set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Neuro-Behçet's Disability Score (NBDS)</title>
          <description>Neuro-Behçet's disability score (NBDS) has been proposed for parenchymal-NBD patients to quantify disabilities. This comprises scores for motor and cognitive status. NBDS is the arithmetic sum of both scores and ranges from 0 to 8, with 8 being death due to NBD. 3 neurologic participants were evaluated.</description>
          <population>Behçet’s disease set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Modified Ranking Score (mRS)</title>
        <description>Mean Modified Rankin Scale (mRS): mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scores range from 0-5 with 5 being the worst outcome. Only 3 participants from neurology clinic were evaluated with this scale.</description>
        <time_frame>30 days</time_frame>
        <population>Behçet’s disease set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Ranking Score (mRS)</title>
          <description>Mean Modified Rankin Scale (mRS): mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scores range from 0-5 with 5 being the worst outcome. Only 3 participants from neurology clinic were evaluated with this scale.</description>
          <population>Behçet’s disease set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ataxia</title>
        <description>Number of the partcipants with ataxia. 3 participants from neurology clinic were evaluated.</description>
        <time_frame>30 days</time_frame>
        <population>Randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Ataxia</title>
          <description>Number of the partcipants with ataxia. 3 participants from neurology clinic were evaluated.</description>
          <population>Randomized set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physical Examination Scores Indicating Change in Muscle Strength</title>
        <description>All 4 extremties were evaluated for muscle strength (upper right, upper left, lower right and lower left) fro each patient. Score 0 is the worst outcome whereas 5 is the best outcome for muscle strength. 3 participants from neurology clinic were assessed.</description>
        <time_frame>30 days</time_frame>
        <population>Behçet’s disease set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Examination Scores Indicating Change in Muscle Strength</title>
          <description>All 4 extremties were evaluated for muscle strength (upper right, upper left, lower right and lower left) fro each patient. Score 0 is the worst outcome whereas 5 is the best outcome for muscle strength. 3 participants from neurology clinic were assessed.</description>
          <population>Behçet’s disease set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upper right extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower right extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper left extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower left extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein (CRP) Values</title>
        <description>Mean CRP (C-reactive protein) value (8 participants)</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) Values</title>
          <description>Mean CRP (C-reactive protein) value (8 participants)</description>
          <population>randomized set</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.58" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythrocyte Sedimentation Rate (ESR)</title>
        <description>Mean erythrocyte sedimentation rate (ESR) value (8 participants)</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <description>Mean erythrocyte sedimentation rate (ESR) value (8 participants)</description>
          <population>randomized set</population>
          <units>mm/H</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAA (Serum Amyloid A)</title>
        <description>Mean Serum Amyloid A value (8 participants)</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>SAA (Serum Amyloid A)</title>
          <description>Mean Serum Amyloid A value (8 participants)</description>
          <population>randomized set</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.66" spread="108.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoptysis</title>
        <description>The number of the participants with hemoptysis</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoptysis</title>
          <description>The number of the participants with hemoptysis</description>
          <population>randomized set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scores (VAS) for Headache</title>
        <description>Headache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. Physician and participant determined the VAS score separately.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scores (VAS) for Headache</title>
          <description>Headache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. Physician and participant determined the VAS score separately.</description>
          <population>randomized set</population>
          <units>average of scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS by participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS by Physicians</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scores (VAS) for Stomachache</title>
        <description>Stomacheache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. VAS is determined separately by physician and the participants.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scores (VAS) for Stomachache</title>
          <description>Stomacheache intensity was measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst pain''. VAS is determined separately by physician and the participants.</description>
          <population>randomized set</population>
          <units>average of scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS by participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS by physicians</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scores (VAS) for Extremity Assessments</title>
        <description>Extremity assessments were measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst possible pain''. The physicians and participants evaluated VAS separately.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scores (VAS) for Extremity Assessments</title>
          <description>Extremity assessments were measured by VAS where score 0 means &quot;no pain,&quot; and score 10 means &quot;the worst possible pain''. The physicians and participants evaluated VAS separately.</description>
          <population>randomized set</population>
          <units>average of scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS by participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS by physicians</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scores (VAS) for Patients' General Assessments</title>
        <description>Participants assessed their own well-being with VAS (visual analogue scale). Score 0 means the best outcome, score 10 is the worst outcome.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scores (VAS) for Patients' General Assessments</title>
          <description>Participants assessed their own well-being with VAS (visual analogue scale). Score 0 means the best outcome, score 10 is the worst outcome.</description>
          <population>randomized set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physician's Global Assessment</title>
        <description>Physician's General Assessments is VAS scale, ranging between 0-5, showing the disease status of participants. Score 0 is the worst outcome; 5 is the best outcome</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Assessment</title>
          <description>Physician's General Assessments is VAS scale, ranging between 0-5, showing the disease status of participants. Score 0 is the worst outcome; 5 is the best outcome</description>
          <population>randomized set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steroid Dose Regimen</title>
        <description>Mean steroid treatment dose (8 participants)</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Dose Regimen</title>
          <description>Mean steroid treatment dose (8 participants)</description>
          <population>randomized set</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BDCAF (Behçet's Disease Current Activity Form)</title>
        <description>BDCAF is an assessment that is made by physician for evaluating the disease activity in last four weeks. Score range is 0 to 12, 0 is the best outcome, 12 is the worst outcome.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>BDCAF (Behçet's Disease Current Activity Form)</title>
          <description>BDCAF is an assessment that is made by physician for evaluating the disease activity in last four weeks. Score range is 0 to 12, 0 is the best outcome, 12 is the worst outcome.</description>
          <population>randomized set</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extremity (Localized) Pain Assessment (VAS)</title>
        <description>Localized pain in the extremities were assessed by visual analogue scale scores ranging between Scale; 0 is the best outcome; 10 is worst.</description>
        <time_frame>30 days</time_frame>
        <population>randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>ACZ885N</title>
            <description>Canakinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Extremity (Localized) Pain Assessment (VAS)</title>
          <description>Localized pain in the extremities were assessed by visual analogue scale scores ranging between Scale; 0 is the best outcome; 10 is worst.</description>
          <population>randomized set</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment</time_frame>
      <desc>An AE is any sign or symptom that occurs during the study treatment plus the # days post treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>ACZ885N</title>
          <description>Canakinumab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an exploratory trial that was not powered for a statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

